Steven Gannon sold $91 of XENE
director at Xenon Pharmaceuticals Inc.. 3 shares at an average of $30.48, traded Jun 5, 2025, filed Jun 6, 2025.
Score components
- +15RoleDirector
- 0Trade size$91 at market
- 0Share of holdings soldSold 0.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-083321, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2025 | SOpen-market sale Common Shares | -3 | $30.48 | $91 | 7,141 | Jun 6, 2025 |
| Jun 5, 2025 | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
Related signals
Other insiders at Xenon Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 75Notable | Xenon Pharmaceuticals Inc. | Thomas Patrick Kelly Chief Financial Officer | $560k 15,000 shares | - | |
| 86Strong | Xenon Pharmaceuticals Inc. | Ian Mortimer PRESIDENT & CEO | $1.1M 30,000 shares | +151% | |
| 49Moderate | XENEsell Xenon Pharmaceuticals Inc. | Sherry Aulin Chief Financial Officer | $771k 18,709 shares | -260% | |
| 17Weak | XENEsell Xenon Pharmaceuticals Inc. | Gary Patou director | $201k 4,891 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.